Hexahistidine
tags (His-tags), incorporated into recombinant proteins
to facilitate purification using metal-affinity chromatography, are
useful binding sites for radiolabeling with [99mTc(CO)3]+ and [188Re(CO)3]+ for molecular imaging and radionuclide therapy. Labeling efficiencies
vary unpredictably, and the method is therefore not universally useful.
To overcome this, we have made quantitative comparisons of radiolabeling
of a bespoke Celluspots array library of 382 His-tag-containing peptide
sequences with [99mTc(CO)3]+ and
[188Re(CO)3]+ to identify key features
that enhance labeling. A selected sequence with 10-fold enhanced labeling
efficiency compared to the most effective literature-reported sequences
was incorporated into an exemplar protein and compared biologically
with non-optimized analogues, in vitro and in vivo. Optimal labeling
with either [99mTc(CO)3]+ or [188Re(CO)3]+ required six consecutive
His residues in the protein sequence, surrounded by several positively
charged residues (Arg or Lys), and the presence of phosphate in the
buffer. Cys or Met residues in the sequence were beneficial, to a
lesser extent. Negatively charged residues were deleterious to labeling.
His-tags with adjacent positively charged residues could be labeled
as much as 40 times more efficiently than those with adjacent negatively
charged residues. 31P NMR of [Re(CO)3(H2O)3]+ and electrophoresis of solutions
of [99mTc(CO)3(H2O)3]+ suggest that phosphate bridges form between cationic residues
and the cationic metal synthon during labeling. The trial optimized
protein, a scFv targeted to the PSMA antigen expressed in prostate
cancer, was readily labeled in >95% radiochemical yield, without
the
need for subsequent purification. Labeling occurred more quickly and
to higher specific activity than comparable non-optimized proteins,
while retaining specific binding to PSMA and prostate cancer in vivo.
Thus, optimized His-tags greatly simplify radiolabeling of recombinant
proteins making them potentially more widely and economically available
for imaging and treating patients.